Filing Analysis
Anixa Biosciences reported the results of its 2026 Annual Meeting of Stockholders held on March 10, 2026. Shareholders re-elected the board of directors, approved executive compensation on an advisory basis, and ratified the company's independent auditor.
🚩 Red Flags
- Significant shareholder opposition to executive compensation, with approximately 33% of the non-broker votes cast against the proposal.
- Notable 'Withheld' votes for directors Emily Gottschalk (1,886,761) and Lewis H. Titterton, Jr. (1,959,312), representing over 20% of the 'For' votes for those individuals.
📋 Key Facts
- A total of 20,805,324 shares of common stock were represented at the meeting, out of 33,379,505 shares entitled to vote.
- Four directors (Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr.) were re-elected to serve until the 2027 annual meeting.
- Executive compensation was approved with 6,025,247 votes for and 2,973,752 votes against.
- Haskell & White LLP was ratified as the independent auditor for the fiscal year ending October 31, 2026, with 20,426,524 votes in favor.
- The company filed an investor presentation as Exhibit 99.1 under Regulation FD disclosure.
Anixa Biosciences announced positive clinical observations in its Phase 1 ovarian cancer CAR-T therapy trial. The company received regulatory approval to proceed with dose escalation beyond the original protocol limits.
📋 Key Facts
- Observed encouraging patient survival data in Phase 1 clinical trial for ovarian cancer CAR-T therapy.
- Regulatory approval granted to enable dose escalation beyond original trial protocol doses.
- Filed under Item 7.01 (Regulation FD Disclosure) via press release dated February 9, 2026.
Anixa Biosciences announced the presentation of final data from its Phase 1 clinical trial for an investigational breast cancer vaccine. The announcement was made in collaboration with The Cleveland Clinic Foundation.
📋 Key Facts
- Company and Cleveland Clinic presented final Phase 1 clinical trial data for a breast cancer vaccine on December 11, 2025.
- The presentation was delivered by Justin Johnson, Ph.D., Program Manager at Cleveland Clinic.
- The filing includes a press release (Exhibit 99.1) and a presentation abstract (Exhibit 99.2).
Anixa Biosciences, Inc. announced the results of its 2025 annual meeting of stockholders held on March 20, 2025. The meeting included the re-election of four directors and advisory votes regarding executive compensation and auditor ratification.
📋 Key Facts
- Annual Meeting held on March 20, 2025.
- Total Voting Stock: 32,196,862 shares; Shares present/represented: 20,691,253 shares.
- Re-elected four directors: Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. to serve until the 2026 annual meeting.
- Ratified the appointment of Haskell & White LLP as independent registered public accounting firm for fiscal year ending October 31, 2025.
- Approved non-binding advisory vote on executive compensation frequency (voted for 1-year frequency).
- Executive compensation approved via non-binding advisory vote.
Anixa Biosciences issued a press release regarding updated positive data from its Phase 1 study of a breast cancer vaccine. The data was presented by Dr. Emily Rhoades from the Cleveland Clinic Foundation.
📋 Key Facts
- Company announced updated positive data for its Phase 1 breast cancer vaccine study on November 8, 2024.
- The presentation was delivered by Dr. Emily Rhoades, FDA/IND Trial Program Manager at Cleveland Clinic.
- Data was presented as part of a scientific poster session (Exhibit 99.2).
Anixa Biosciences entered into a Joint Development and Option Agreement with the Cleveland Clinic Foundation (CCF) to collaborate on cancer vaccine development. The agreement includes non-refundable option fees and structured development funding tranches.
🚩 Red Flags
- Significant cash outflows required via non-refundable fees and three distinct development funding tranches through 2026.
📋 Key Facts
- Agreement effective date: May 3, 2024.
- The partnership focuses on developing vaccines for the prevention or treatment of cancers.
- Company must pay a non-refundable option fee by May 23, 2024.
- Development funding is split into three tranches: May 8, 2024; January 31, 2025; and January 31, 2026.
- The agreement grants Anixa an exclusive option for a worldwide, royalty-bearing license to CCF inventions related to the project.
- IP ownership: Inventions are owned by the inventing party, while Joint Inventions are owned jointly.
Anixa Biosciences, Inc. reported the results of its 2024 annual meeting of stockholders held on March 21, 2024. The company successfully re-elected four directors and ratified the appointment of its independent auditor.
📋 Key Facts
- Annual Meeting held on March 21, 2024.
- Re-election of Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. to the Board of Directors.
- Non-binding advisory approval of executive compensation (Say-on-Pay).
- Ratification of Haskell & White LLP as independent registered public accounting firm for fiscal year ending October 31, 2024.
- Total Voting Stock present or represented: 18,521,786 shares out of 31,711,753 total shares.